| Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in … A Paulus, S Akhtar, H Yousaf, A Manna, SM Paulus, Y Bashir, ... Blood cancer journal 7 (5), e565-e565, 2017 | 56 | 2017 |
| Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib-or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells A Paulus, S Akhtar, TR Caulfield, K Samuel, H Yousaf, Y Bashir, ... Blood cancer journal 6 (11), e492-e492, 2016 | 50 | 2016 |
| Drug resistance alters CD38 expression and in vitro response to daratumumab in Waldenstrom macroglobulinemia cells A Paulus, S Akhtar, Y Bashir, SM Paulus, H Yousaf, V Roy, S Ailawadhi, ... Blood 128 (22), 3018, 2016 | 7 | 2016 |
| Targeting Bcl-2 Enhances the Anti-Tumor Effects of Lenalidomide and Dexamethasone in in Vitro and In Vivo Models of Multiple Myeloma A Paulus, S Akhtar, Y Bashir, SM Paulus, R Menghani, V Roy, ... Blood 128 (22), 4480, 2016 | 2 | 2016 |
| Waldenstrom macroglobulinemia cells modulate mitochondrial bioenergetics and induce a respiratory hyper-drive state upon acquisition of ibrutinib-resistance A Paulus, S Akhtar, R Hudec, SM Paulus, Y Bashir, TE Witzig, S Ansell, ... Blood 128 (22), 2761, 2016 | 1 | 2016 |
